Q4 Earnings Estimate for UNCY Issued By HC Wainwright

Market Beat
2025.05.29 11:42

HC Wainwright analysts have issued Q4 2026 earnings estimates for Unicycive Therapeutics (NASDAQ: UNCY), projecting earnings of $0.47 per share. The firm maintains a "Buy" rating with a $9.00 price target. Currently, the consensus estimate for the full-year earnings is ($0.23) per share. Unicycive's stock opened at $0.59, with a 52-week range of $0.20 to $0.96. The company focuses on developing therapies for kidney diseases, including Renazorb and UNI 494.

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities research analysts at HC Wainwright issued their Q4 2026 earnings per share (EPS) estimates for Unicycive Therapeutics in a research note issued on Tuesday, May 27th. HC Wainwright analyst S. Ramakanth expects that the company will earn $0.47 per share for the quarter. HC Wainwright has a "Buy" rating and a $9.00 price target on the stock. The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($0.23) per share.

Get Unicycive Therapeutics alerts:

Separately, Guggenheim assumed coverage on shares of Unicycive Therapeutics in a report on Monday, April 21st. They issued a "buy" rating and a $6.00 price target on the stock.

Check Out Our Latest Stock Report on UNCY

Unicycive Therapeutics Stock Performance

Shares of NASDAQ UNCY opened at $0.59 on Wednesday. Unicycive Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $0.96. The stock has a market cap of $71.30 million, a PE ratio of -0.61 and a beta of 2.14. The stock has a fifty day moving average of $0.59 and a 200-day moving average of $0.61.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.09.

Institutional Trading of Unicycive Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Northern Trust Corp increased its stake in Unicycive Therapeutics by 142.4% in the fourth quarter. Northern Trust Corp now owns 58,181 shares of the company's stock valued at $46,000 after acquiring an additional 34,183 shares during the last quarter. XTX Topco Ltd boosted its holdings in shares of Unicycive Therapeutics by 142.2% in the 4th quarter. XTX Topco Ltd now owns 171,463 shares of the company's stock worth $136,000 after purchasing an additional 100,679 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Unicycive Therapeutics by 30.3% during the 4th quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock valued at $417,000 after purchasing an additional 122,089 shares during the last quarter. Acuta Capital Partners LLC raised its holdings in shares of Unicycive Therapeutics by 16.4% during the 4th quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company's stock valued at $1,829,000 after buying an additional 323,801 shares in the last quarter. Finally, Vivo Capital LLC lifted its position in Unicycive Therapeutics by 14.0% in the 1st quarter. Vivo Capital LLC now owns 11,370,152 shares of the company's stock worth $6,537,000 after buying an additional 1,400,000 shares during the last quarter. 40.42% of the stock is owned by institutional investors.

Unicycive Therapeutics Company Profile

(Get Free Report)

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.

Further Reading

  • Five stocks we like better than Unicycive Therapeutics
  • How to Choose Top Rated Stocks
  • 3 Reasons Wix Could Rally 50% Into the Summer
  • 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
  • Advance Auto Parts: Did Earnings Defuse Tariff Concerns?
  • Russell 2000 Index, How Investors Use it For Profitable Trading
  • 3 Beaten-Down Stocks Trading 50% Below Their 52-Week Highs

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Unicycive Therapeutics Right Now?

Before you consider Unicycive Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicycive Therapeutics wasn't on the list.

While Unicycive Therapeutics currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Source: Market Beat The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.